(97) utilized nilotinib, a second-generation BCR-ABL inhibitor, to treat newly diagnosed CML patients and observed a rapid decrease in CD34+lin-Ph+ cells in the bone marrow, with total clearance of the analyzed samples at 12 months of treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.